[Jackie07]

Found this abstract about the different survival predicting factors. Lower grades tends to recur after very long period of time (wondered if it's because they weren't treated aggressively the first time around.) Keep in mind the time period covered in the study includes the many years before Herceptin was approved by FDA (in 2005).

Breast Cancer Res Treat. 2011 May 20. [Epub ahead of print]
Biologic markers determine both the risk and the timing of recurrence in breast cancer.

Esserman LJ, Moore DH, Tsing PJ, Chu PW, Yau C, Ozanne E, Chung RE, Tandon VJ, Park JW, Baehner FL, Kreps S, Tutt AN, Gillett CE, Benz CC.
Source

Department of Surgery and Radiology, University of California, San Francisco, CA, USA, laura.esserman@ucsfmedctr.org.

Abstract

Breast cancer has a long natural history. Established and emerging biologic markers address overall risk but not necessarily timing of recurrence.

346 adjuvant naïve breast cancer cases from Guy's Hospital with 23 years minimum follow-up and archival blocks were recut and reassessed for hormone-receptors (HR), HER2-receptor and grade. Disease-specific survival (DSS) was analyzed by recursive partitioning.

To validate insights from this analysis, gene-signatures (proliferative and HR-negative) were evaluated for their ability to predict early versus late metastatic risk in 683 node-negative, adjuvant naïve breast cancers annotated with expression microarray data. Risk partitioning showed that adjuvant naïve node-negative outcome risk was primarily partitioned by tumor receptor status and grade but not tumor size.

HR-positive and HER2-negative (HRpos) risk was partitioned by tumor grade; low grade cases have very low early risk but a 20% fall-off in DSS 10 or more years after diagnosis. Higher grade HRpos cases have risk over >20 years. Triple-negative (Tneg) and HER2-positive (HER2pos) cases DSS events occurred primarily within the first 5 years.

Among node-positive cases, only low grade conferred late risk, suggesting that proliferative gene signatures that identify proliferation would be important for predicting early but not late recurrence.

Using pooled data from four publicly available data sets for node-negative tumors annotated with gene expression and outcome data, we evaluated four prognostic gene signatures: two proliferation-based and two immune function-based.

Tumor proliferative capacity predicted early but not late metastatic risk for HRpos cases. The immune function or HRneg specific signatures predicted only early metastatic risk in Tneg and HER2pos cases. Breast cancer prognostic signatures need to inform both risk and timing of metastatic events and may best be applied within subsets.

Current signatures predict for outcome risk within 5 years of diagnosis. Predictors of late risk for HR positive disease are needed.